[의학신문·일간보사=김영주 기자]’Rivaro’, a treatment for dyslipidemia (Picture), the first online international academic symposium will be held.
 |
JW Joongwae Pharmaceutical announced on the 5th that the 4th Rivaro International Webinar will be held at 8 p.m. on the 10th, targeting cardiovascular disease-related practitioners, including general practitioners in 26 countries around the world.
The’Libaro International Webinar’, which was planned as part of Untect Marketing last year, showed high interest as more than 1,200 global medical staff participated during the 3rd session.
This webinar was presented by Masato Odawara, a professor at the University of Tokyo, as a speaker, based on the research results of’J-PREDICT’ and’REAL-CAD’, which are the academic basis for Libaro’s’diabetes safety certification in 31 countries around the world’ Conduct the discussion.
Prof. Masato Odawara (Department of Endocrinology and Metabolism, Japan’s Taoist University) proved that “Pitavastatin has an 18% lower risk of diabetes inducement compared to placebo” in a’J-PREDICT’ study published in 2014.
In addition, the’REAL-CAD’ study is a clinical result conducted by Professor Takeshi Kimura (Department of Cardiovascular Medicine, Kyoto University, Japan) on 13,054 stable coronary artery patients from January 2010 to March 2013. This study compares the incidence of cardiovascular disease between high-dose 4mg and low-dose 1mg in Asian patients, and is the most cited academic evidence for the excellence of pitavastatin.
Professor Masato Odawara said,’Is your statin treatment perfect? We plan to exchange opinions with global medical staff under the theme of’Let’s think again in the post-statin era’.
Reporter Kim Young-joo [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>